Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $17.44, for a total value of $959,200.00. Following the transaction, the chief executive officer now directly owns 520,661 shares of the company's stock, valued at $9,080,327.84. The trade was a 9.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Saurabh Saha also recently made the following trade(s):
- On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total transaction of $1,615,176.16.
- On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.23, for a total value of $5,450.77.
- On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.89, for a total transaction of $928,950.00.
- On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total value of $30,479.04.
- On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44.
- On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.80, for a total value of $350,839.00.
Centessa Pharmaceuticals Price Performance
Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis
From Weiss Ratings | Ad
Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%.
Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …
Find out details on these three critical Nvidia partners immediately.
Shares of Centessa Pharmaceuticals stock opened at $17.16 on Friday. The company's 50-day moving average price is $16.64 and its two-hundred day moving average price is $13.57. The stock has a market cap of $2.26 billion, a PE ratio of -11.22 and a beta of 1.52. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 52 week low of $6.65 and a 52 week high of $18.97.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. HighMark Wealth Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $840,000. TD Asset Management Inc raised its stake in Centessa Pharmaceuticals by 40.5% during the second quarter. TD Asset Management Inc now owns 321,168 shares of the company's stock worth $2,900,000 after acquiring an additional 92,524 shares in the last quarter. American Century Companies Inc. boosted its position in Centessa Pharmaceuticals by 1.3% in the second quarter. American Century Companies Inc. now owns 935,151 shares of the company's stock valued at $8,444,000 after buying an additional 12,031 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $148,000. Finally, Farallon Capital Management LLC increased its holdings in Centessa Pharmaceuticals by 438.0% during the 2nd quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock valued at $18,024,000 after purchasing an additional 1,625,000 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities analysts recently weighed in on CNTA shares. Guggenheim raised their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Friday, November 15th. BMO Capital Markets boosted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a research report on Monday, September 16th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 target price for the company. Morgan Stanley upgraded Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $11.00 to $26.00 in a research report on Thursday, September 19th. Finally, Jefferies Financial Group upped their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $25.83.
View Our Latest Research Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Company Profile
(
Get Free Report)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
